France Next-Generation Sequencing Market to Grow with a CAGR of 19.01% through 2028

Technological advancements, collaborative research efforts and a growing emphasis on precision medicine are expected to drive the France Next-Generation Sequencing Market growth in the forecast period, 2024-2028.

According to TechSci Research report, “France Next-Generation Sequencing Market – By Region, Competition, Forecast and Opportunities, 2028”, the France Next-Generation Sequencing Market stood at USD 495.36 million in 2022 and is anticipated to grow with a CAGR of 19.01% in the forecast period, 2024-2028. This can be attributed to the rising prevalence of genetic disorders and oncology research. The increasing incidence of genetic disorders and the growing emphasis on understanding the genetic basis of cancer are fueling the demand for NGS in clinical and research settings. NGS technologies provide a powerful tool for identifying genetic mutations, assessing cancer risk, and guiding targeted therapies, contributing to advancements in oncology research and patient care.

Furthermore, the trend toward decentralized testing and point-of-care diagnostics is likely to influence the development of portable NGS devices. Compact and user-friendly sequencing platforms that can deliver rapid results at the point of care are anticipated to emerge. This trend has the potential to facilitate timely and on-site genomic analysis, particularly in clinical settings where rapid decision-making is critical.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "France Next-Generation Sequencing Market”

The France Next-Generation Sequencing (NGS) market is experiencing significant growth and innovation, driven by advancements in genomic research, personalized medicine, and increasing applications across various fields. Key players in the market are actively contributing to technological developments, resulting in improved sequencing accuracy, reduced costs, and enhanced data analysis capabilities.

The France NGS market is characterized by a diverse range of applications, including genomics, transcriptomics, epigenomics, and metagenomics. These applications find utility in research institutions, clinical diagnostics, pharmaceuticals, and biotechnology companies. The market is witnessing a surge in demand for NGS technologies, fueled by the rising prevalence of genetic disorders, cancer, and infectious diseases.

The France Next-Generation Sequencing Market is segmented into product, technology, end user, application, regional distribution, and company.

Based on its technology, Sequencing by Synthesis (SBS) is poised to dominate the Next-Generation Sequencing (NGS) market in France due to its unparalleled advantages and technological advancements. With its ability to simultaneously sequence millions of DNA strands, SBS offers high throughput and cost-effectiveness, making it an attractive choice for genomic research and clinical applications. The precision and accuracy of SBS technology contribute to its widespread adoption in diverse fields such as personalized medicine, agriculture, and environmental studies. Additionally, ongoing research and development efforts continue to enhance the efficiency and scalability of SBS, ensuring its sustained relevance in the rapidly evolving genomics landscape. As the demand for comprehensive and precise genomic data intensifies, Sequencing by Synthesis is well-positioned to emerge as the dominant technology in the French NGS market, driving innovation and transformative breakthroughs in various scientific disciplines.

Based on application, Biomarkers and cancer-related applications are poised to dominate the Next-Generation Sequencing (NGS) market in France due to the critical role they play in advancing personalized medicine and improving patient outcomes. The increasing focus on precision medicine has heightened the demand for NGS technologies capable of identifying and analyzing biomarkers associated with various cancers. NGS facilitates the comprehensive profiling of genomic alterations, enabling healthcare professionals to tailor treatment plans based on the unique genetic makeup of individual patients. This approach not only enhances the efficacy of cancer therapies but also contributes to early detection and monitoring of the disease. The continuous advancements in NGS technologies, coupled with a growing emphasis on cancer research and diagnostics, position biomarkers and cancer-related applications as central drivers in the French NGS market. The ability of NGS to unravel the complexities of cancer genetics underscores its pivotal role in shaping the future of oncology in the region.

Major companies operating in France Next-Generation Sequencing Market are:

• Illumina France
• Roche Diagnostics France SAS
• Agilent Technologies, Inc.
• Perkinelmer Inc.
• Amgen Inc.
• Takara Bio Europe

Download Free Sample Report

Customers can also request for 10% free customization on this report

“France Next-Generation Sequencing Market is set to undergo a transformative journey, with innovation at its core. The anticipated developments not only promise to enhance the capabilities of NGS technologies but also hold the potential to revolutionize our understanding of genomics and its applications in healthcare, research, and beyond,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

“France Next-Generation Sequencing Market By Product (Consumables, Platforms, Services), By Consumables (Sample preparation consumables, Other Consumables), By Platforms (HiSeq series, MiSeq series, ION Torrent, SOLiD, Pacbio Rs II and Sequel system, Other Sequencing Platforms), By Services (Sequencing Services, Data management services), By Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Sequencing by Ligation, Single Molecule Real Time Sequencing and Others), By End User (Academic & Clinical Research Centers, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics and Others), By Application (Biomarkers & Cancer, Diagnostics, Reproductive Health, Personalized Medicine, Agriculture & Animal Research and Others), By Region, By Competition Forecast & Opportunities, 2018-2028F”, has evaluated the future growth potential of France Next-Generation Sequencing Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in France Next-Generation Sequencing Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com